Home Featured Page 158

Featured

Latest

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

Alexander Beiner – Psychedelics, Culture, and the Games We Play

PT341 – Monnica Williams, Ph.D. – Racism, Trauma, Research, and Psychedelics

Ecstasy for the 21st Century: Designer Drugs to Improve MDMA Therapy

HAVN Life Announces Financing Commitment of CAD$9,000,000 through the issuance of...

Incannex Receives Ethics Approval to Commence Phase 1 Clinical Trial of...

PT340 – Joost Breeksema – The Interdisciplinary Conference on Psychedelic Research...

The Doors of Expression: LSD Alters Epigenetics and Protein Induction

COMPASS Pathways appoints Kabir Nath as Chief Executive Officer

Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting...

Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of...

1...157158159...303 Page 158 of 303

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

Alexander Beiner – Psychedelics, Culture, and the Games We Play

PT341 – Monnica Williams, Ph.D. – Racism, Trauma, Research, and Psychedelics

Ecstasy for the 21st Century: Designer Drugs to Improve MDMA Therapy

HAVN Life Announces Financing Commitment of CAD$9,000,000 through the issuance of...

Incannex Receives Ethics Approval to Commence Phase 1 Clinical Trial of...

PT340 – Joost Breeksema – The Interdisciplinary Conference on Psychedelic Research...

The Doors of Expression: LSD Alters Epigenetics and Protein Induction

COMPASS Pathways appoints Kabir Nath as Chief Executive Officer

Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting...

Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of...

Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of...

EDITOR PICKS

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY